Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.

An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers

Tseng, Chin-Hsiao, Lee, Kuo-Yang, Tseng, Farn-Hsuan · 2015 · Journal of Environmental Science and Health, Part C

Abstract

Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1 receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) inhibitors, are widely used by clinicians for glucose lowering in patients with type 2 diabetes mellitus. These agents have benefits of a lower risk of hypoglycemia, being neutral for body weight for DPP-4 inhibitors and having a potential for weight reduction with GLP-1R agonists. They may also have a neutral or beneficial cardiovascular effect. Despite these benefits, an increased risk of cancer (especially pancreatic cancer and thyroid cancer) associated with incretin-based therapies has been reported. In this article, we reviewed related literature of experimental animal and observational human studies, clinical trials, and meta-analyses published until December 15, 2014. Current studies suggested a probable role of GLP-1R activation on the development of pancreatic cancer and thyroid cancer in rodents, but such an effect in humans is not remarkable due to the lower or lack of expression of GLP-1R on human pancreatic ductal cells and thyroid tissues. Findings in human studies are controversial and inconclusive. In the analyses of the US Food and Drug Administration adverse events reporting system, a significantly higher risk of pancreatic cancer was observed for GLP-1R agonists and DPP-4 inhibitors, but a significantly higher risk of thyroid cancer was only observed for GLP-1R agonists. Such a highe…

Overview

Integrity signals

Registry

Crossref · 10.1080/10590501.2015.1003496

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 195 references

Research works printed but not linked: 9

  1. International Diabetes Federation Diabetes Atlas, 6th ed.
  2. Lin HW, 2014, Int J Endocrinol, 2014, 719578
  3. 10.1210/endo.141.12.7806 · doi:10.1210/endo.141.12.7806 · Paper page
  4. Faillie JL, 2014, Acta Diabetol, 51, 491
  5. 10.2967/jnumed.106.038679 · DOI · Paper page
  6. Huang CJ, 2014, J Chin Med Assoc
  7. Navas-Carrillo D, 2014, Biochim Biophys Acta, 1846, 468
  8. Nagy R, 2014, Horm Cancer
  9. Kwon MJ, 2014, Pancreas

Cited by

See all 57

Metadata

Authors
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H.
Affiliations
  • National Taiwan University Hospital (TW)
  • China Medical University Hospital (TW)
  • University of Southern California (US)
Corresponding author
Tseng, Chin-Hsiao
Venue
Journal of Environmental Science and Health, Part C
Published
2015-01-02
Volume
33
Issue
1
Pages
67-124
ISSN
  • 1059-0501 (ISSN-L)
  • 1532-4095
OpenAlex
W2140307375
Cited by
49
References
195
Citations by year
2025: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 13 · 2015: 3
FWCI
7.51
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Environmental Science and Health Part C (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, cancer risk, pancreatic cancer, thyroid cancer, type 2 diabetes, adverse drug reactions
MeSH terms
Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Pancreatic Neoplasms, Risk Factors, Thyroid Neoplasms, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. https://app.cochat.ai/papers/10.1080/10590501.2015.1003496
The paper
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015). An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C. https://doi.org/10.1080/10590501.2015.1003496

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.